在高心血管风险患者中对奥比塞特拉皮布的安全性和有效性
Stephen J Nicholls1, Adam J Nelson1, Marc Ditmarsch2
1Victorian Heart Institute, Monash University, Clayton, VIC, Australia.
The New England journal of medicine
|May 8, 2025
概括
在高风险患者中,欧比塞特拉皮显著降低了29.9%的LDL胆固醇. 这种胆固醇转移蛋白抑制剂在预防心血管事件方面表现有前途.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥比塞特拉皮布是一种选择性胆固醇转移蛋白抑制剂.
- 它在高风险心血管患者中的疗效和安全性需要进一步描述.
研究的目的:
- 评估在患有心血管事件高风险的患者中对obicetrapib的疗效和安全性.
主要方法:
- 一个跨国,随机,安慰剂对照试验.
- 包括患有家族性高胆固醇血症或动脉样硬化心血管疾病的患者,接受最大限度的降脂疗法.
- 从基线到第84天LDL胆固醇的评估百分比变化.
主要成果:
- 与安慰剂相比,奥比塞特拉皮布降低了LDL胆固醇的29.9% (P<0.001).与安慰剂相比,该药物降低了LDL胆固醇的29.9% (P<0.001).
- 不良事件的发生率在各组之间是相似的.
结论:
- 在高风险患者中,欧比塞特拉皮布有效降低了LDL胆固醇.
- 这种药物是管理心血管风险的潜在治疗选择.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
392
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
392
Antiepileptic Drugs: Potassium Channel Activators
126
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
126
Therapeutic Index
4.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.0K
Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K


